10x Genomics shares drop 12% on disappointing second-quarter preliminary results by

© Reuters. 10x Genomics (TXG) Shares drop 12% on disappointing Q2 preliminary results

By David Kirakosyan

Shares of 10x Genomics, Inc. (NASDAQ:) is down more than 12% after hours following the company’s preliminary Q2 results, with revenue projected at approximately $114.5 million (down 1% year-over-year), Missing Street’s estimate of $127.7. million.

“Our second quarter results fell short of our expectations,” said Serge Saxonov, Co-Founder and CEO of 10x Genomics. “We continue to believe strongly in the long-term opportunity, technological leadership, and underlying strength of the market. We are more excited than ever to unleash the full potential of bioengineering.” space and single cell.”

Source link


Kig News: Update the world's latest breaking news online of the day, breaking news, politics, society today, international mainstream news .Updated news 24/7: Entertainment, the World everyday world. Hot news, images, video clips that are updated quickly and reliably

Related Articles

Back to top button